RESEARCH TRIANGLE PARK, N.C. — BioMachines
, a developer and manufacturer of automation tools for use in the acceleration of drug discovery, has signed on a European distribution partner.
Working with BioMachines will be Disruptive Technologies, which is based in Paris.
"Europe is a very large market and there is a demand for our products", said Tom Larrichio, BioMachines' chief executive officer. "We are very pleased to have found a company like Disruptive Technologies, whose principals have deep knowledge and understanding of the proteomics and genomics market in Europe. They will serve us well."
Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
